摘要
目的探讨阿托伐他汀与辅酶Q10联合应用对经皮冠脉介入(PCI)术后血清超敏C反应蛋白(hs-CRP)及妊娠相关蛋白A(PAPP-A)的影响。方法选取经PCI治疗单支病变的不稳定型心绞痛患者60例,随机分为对照组(n=20)、阿伐他汀组(n=20)和阿伐他汀+辅酶Q10组(联合组,n=20)。对照组采用常规治疗,阿伐他汀组采用常规治疗+阿托伐他汀(40mg,1次/晚),联合组采用常规治疗+阿托伐他汀(40mg,1次/晚)+辅酶Q10(10mg,tid)。测定所有患者术前、术后24h及术后30d的hs-CRP、PAPP-A水平。结果①所有组别术后24h和术后30d的hs-CRP、PAPP-A水平均较术前明显升高(P<0.05),但术后30d低于术后24h,差异有统计学意义(P<0.05);②与对照组比较,联合组和阿伐他汀组术后24h和术后30d的hs-CRP和PAPP-A水平均较低,差异有统计学意义(P<0.05);③与阿伐他汀组比较,联合组术后24h和30d的hs-CRP和PAPP-A水平均较低,差异有统计学意义(P<0.05)。结论阿托伐他丁与辅酶Q10具有协同抗炎作用。
Objective To investigate the influences of combination of atorvastatin and co-enzyme Q10 on serum high sensitivity C-reactive protein ( hs-CRP ) and pregnancy-associated plasma protein-A ( PAPP-A ) after percutaneous coronary intervention ( PCI ) . Methods The patients ( n =60 ) with unstable angina single vessel lesion treated with PCI were randomly divided into control group ( n =20 ) , atorvastatin group ( n =20 ) and atorvastatin combining co-enzyme Q10 group ( combining group, n =20 ) . The control group was treated with routine therapy, atorvastatin group, with atorvastatin ( 40 mg, once every night ) besides of routine therapy, and combining group, with atorvastatin ( 40 mg, once every night ) and co-enzyme Q10 ( 10 mg, three time a day ) besides of routine therapy. The levels of serum hs-CRP and PAPP-A were detected before PCI, and 24 hours and 30 days after PCI. Results ① The levels of serum hs-CRP and PAPP-A were higher in all groups 24 hours and 30 days after PCI than those before PCI ( P 0.05 ) , and were lower 30 days after PCI than those 24 hours after PCI ( P 0.05 ) . ② Compared with control group, the levels of serum hs-CRP and PAPP-A were lower in combining group and atorvastatin group 24 hours and 30 days after PCI ( P 0.05). ③ Compared with atorvastatin group, the levels of serum hs-CRP and PAPP-A were lower in combining group 24 hours and 30 days after PCI ( P 0.05). Conclusion After PCI the levels of serum hs-CRP and PAPP-A are all increased. Atorvastatin has the effect of reducing inflammatory level, which will be improved if atorvastatin is combined with co-enzyme Q10.
出处
《中国循证心血管医学杂志》
2012年第5期465-467,共3页
Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词
经皮冠脉介入术
超敏C-反应蛋白
妊娠相关蛋白A
阿托伐他汀
辅酶Q10
Coronary diseases
Percutaneous coronary intervention
high-sensitive C-reactive protein
Pregnancy-associated plasma protein-A
Antilipemic agents
Co-enzyme Q10